Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice

Giuseppe Lattanzio, Claude Libert, Massimo Aquilina, Manuela Cappelletti, Gennaro Ciliberto, Piero Musiani, Valeria Poli

Research output: Contribution to journalArticle

Abstract

Interleukin (IL)-6 is known to be an essential growth factor for myeloma cells, both in vitro and in vivo. In mice, IL-6 is required for development of B cell tumors upon infection with a retrovirus expressing the myc/raf oncogenes. In the present study, we used the pristane-oil-induced plasmacytoma model, which more closely mimics tumor transformation and progression in human multiple myeloma. Also using this system, we found that IL-6-deficient BALB/c mice are protected against tumor development. Although the pristane-induced inflammatory reaction was less pronounced in IL-6- deficient mice versus their wild-type littermates, both B cell differentiation and plasma cell formation took place, and even morphological evidence of plasma cell transformation was detected, albeit at a low frequency. However, in the absence of IL-6, there were never signs of uncontrolled proliferation of either normal B lymphocytes or tumor cells, suggesting that the role of IL-6 in murine plasmacytoma and possibly also in human multiple myeloma is to ensure abnormal survival and proliferation of previously transformed tumor cells and therefore tumor development and progression.

Original languageEnglish
Pages (from-to)689-696
Number of pages8
JournalAmerican Journal of Pathology
Volume151
Issue number3
Publication statusPublished - Sep 1997

Fingerprint

Plasmacytoma
Interleukin-6
Oils
Neoplasms
B-Lymphocytes
Plasma Cells
Multiple Myeloma
myc Genes
Retroviridae
pristane
Cell Differentiation
Intercellular Signaling Peptides and Proteins
Survival
Infection

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Lattanzio, G., Libert, C., Aquilina, M., Cappelletti, M., Ciliberto, G., Musiani, P., & Poli, V. (1997). Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. American Journal of Pathology, 151(3), 689-696.

Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. / Lattanzio, Giuseppe; Libert, Claude; Aquilina, Massimo; Cappelletti, Manuela; Ciliberto, Gennaro; Musiani, Piero; Poli, Valeria.

In: American Journal of Pathology, Vol. 151, No. 3, 09.1997, p. 689-696.

Research output: Contribution to journalArticle

Lattanzio, G, Libert, C, Aquilina, M, Cappelletti, M, Ciliberto, G, Musiani, P & Poli, V 1997, 'Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice', American Journal of Pathology, vol. 151, no. 3, pp. 689-696.
Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. American Journal of Pathology. 1997 Sep;151(3):689-696.
Lattanzio, Giuseppe ; Libert, Claude ; Aquilina, Massimo ; Cappelletti, Manuela ; Ciliberto, Gennaro ; Musiani, Piero ; Poli, Valeria. / Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. In: American Journal of Pathology. 1997 ; Vol. 151, No. 3. pp. 689-696.
@article{acd854a875694859b8a3c51aaf8390cf,
title = "Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice",
abstract = "Interleukin (IL)-6 is known to be an essential growth factor for myeloma cells, both in vitro and in vivo. In mice, IL-6 is required for development of B cell tumors upon infection with a retrovirus expressing the myc/raf oncogenes. In the present study, we used the pristane-oil-induced plasmacytoma model, which more closely mimics tumor transformation and progression in human multiple myeloma. Also using this system, we found that IL-6-deficient BALB/c mice are protected against tumor development. Although the pristane-induced inflammatory reaction was less pronounced in IL-6- deficient mice versus their wild-type littermates, both B cell differentiation and plasma cell formation took place, and even morphological evidence of plasma cell transformation was detected, albeit at a low frequency. However, in the absence of IL-6, there were never signs of uncontrolled proliferation of either normal B lymphocytes or tumor cells, suggesting that the role of IL-6 in murine plasmacytoma and possibly also in human multiple myeloma is to ensure abnormal survival and proliferation of previously transformed tumor cells and therefore tumor development and progression.",
author = "Giuseppe Lattanzio and Claude Libert and Massimo Aquilina and Manuela Cappelletti and Gennaro Ciliberto and Piero Musiani and Valeria Poli",
year = "1997",
month = "9",
language = "English",
volume = "151",
pages = "689--696",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice

AU - Lattanzio, Giuseppe

AU - Libert, Claude

AU - Aquilina, Massimo

AU - Cappelletti, Manuela

AU - Ciliberto, Gennaro

AU - Musiani, Piero

AU - Poli, Valeria

PY - 1997/9

Y1 - 1997/9

N2 - Interleukin (IL)-6 is known to be an essential growth factor for myeloma cells, both in vitro and in vivo. In mice, IL-6 is required for development of B cell tumors upon infection with a retrovirus expressing the myc/raf oncogenes. In the present study, we used the pristane-oil-induced plasmacytoma model, which more closely mimics tumor transformation and progression in human multiple myeloma. Also using this system, we found that IL-6-deficient BALB/c mice are protected against tumor development. Although the pristane-induced inflammatory reaction was less pronounced in IL-6- deficient mice versus their wild-type littermates, both B cell differentiation and plasma cell formation took place, and even morphological evidence of plasma cell transformation was detected, albeit at a low frequency. However, in the absence of IL-6, there were never signs of uncontrolled proliferation of either normal B lymphocytes or tumor cells, suggesting that the role of IL-6 in murine plasmacytoma and possibly also in human multiple myeloma is to ensure abnormal survival and proliferation of previously transformed tumor cells and therefore tumor development and progression.

AB - Interleukin (IL)-6 is known to be an essential growth factor for myeloma cells, both in vitro and in vivo. In mice, IL-6 is required for development of B cell tumors upon infection with a retrovirus expressing the myc/raf oncogenes. In the present study, we used the pristane-oil-induced plasmacytoma model, which more closely mimics tumor transformation and progression in human multiple myeloma. Also using this system, we found that IL-6-deficient BALB/c mice are protected against tumor development. Although the pristane-induced inflammatory reaction was less pronounced in IL-6- deficient mice versus their wild-type littermates, both B cell differentiation and plasma cell formation took place, and even morphological evidence of plasma cell transformation was detected, albeit at a low frequency. However, in the absence of IL-6, there were never signs of uncontrolled proliferation of either normal B lymphocytes or tumor cells, suggesting that the role of IL-6 in murine plasmacytoma and possibly also in human multiple myeloma is to ensure abnormal survival and proliferation of previously transformed tumor cells and therefore tumor development and progression.

UR - http://www.scopus.com/inward/record.url?scp=0030929261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030929261&partnerID=8YFLogxK

M3 - Article

C2 - 9284817

AN - SCOPUS:0030929261

VL - 151

SP - 689

EP - 696

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -